SME Times is powered by   
Search News
Just in:   • Equity indices break two-day losing streak on value buying  • IMF urges Sri Lanka to tighten monetary policy  • Global semiconductor sales to reach $676 bn this year: Gartner  • Tinna Rubber hits upper circuit, investors accumulate 900% returns in year  • Availability of jobs in Japan improves for 1st time in 3 yrs 
Last updated: 27 Sep, 2014  

Licensing Terms and Agreements in Pharma, Biotech, Diagnostics

PR Newswire | 08 Jul, 2014
MUMBAI, India: The "Licensing Terms and Agreements in Pharma, Biotech and Diagnostics" report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the world's leading life science companies. The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Request for Sample Pages:

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst

Chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technology and therapeutic area. Each deal title links via Web link to an online version of the actual contract document, providing easy access to each contract document on demand.

Key benefits

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

    In-depth understanding of licensing partnering deal trends since 2009
    Analysis of the structure of licensing agreements with numerous real life case studies
    Comprehensive listing of all licensing deals since 2009, together with deal terms, value and press release
    Comprehensive access to actual licensing contracts entered into by the world's life science companies
    Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
    Insight into the terms included in a licensing agreement, together with real world clause examples
    Understand the key deal terms companies have agreed in previous deals
    Undertake due diligence to assess suitability of your proposed deal terms for partner companies

To view the Abstract and TOC:

Sector Specific Reports on Biotech and Diagnostics:

Contact Details:

Bharat Book Bureau
USA/Canada - +1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773

SOURCE Bharat Book Bureau

Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 27 Apr, 2022
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter